Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Melinta Therapeutics, Inc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Melinta Therapeutics, Inc - Product Pipeline Review - 2014', provides an overview of the Melinta Therapeutics, Inc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Melinta Therapeutics, Inc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Melinta Therapeutics, Inc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Melinta Therapeutics, Inc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Melinta Therapeutics, Inc's pipeline products Reasons to buy - Evaluate Melinta Therapeutics, Inc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Melinta Therapeutics, Inc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Melinta Therapeutics, Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Melinta Therapeutics, Inc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Melinta Therapeutics, Inc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Melinta Therapeutics, Inc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Melinta Therapeutics, Inc Snapshot 5 Melinta Therapeutics, Inc Overview 5 Key Information 5 Key Facts 5 Melinta Therapeutics, Inc - Research and Development Overview 6 Key Therapeutic Areas 6 Melinta Therapeutics, Inc - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Melinta Therapeutics, Inc - Pipeline Products Glance 12 Melinta Therapeutics, Inc - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Melinta Therapeutics, Inc - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Melinta Therapeutics, Inc - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Melinta Therapeutics, Inc - Drug Profiles 16 delafloxacin 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 radezolid 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 RX-02 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 RX-04 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 RX-05 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 RXP-792 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 RXP-873 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 RXP-763 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 RXP-766 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 RXP-770 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 RXP-793 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 RXP-808 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Melinta Therapeutics, Inc - Pipeline Analysis 34 Melinta Therapeutics, Inc - Pipeline Products by Target 34 Melinta Therapeutics, Inc - Pipeline Products by Route of Administration 35 Melinta Therapeutics, Inc - Pipeline Products by Molecule Type 36 Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action 37 Melinta Therapeutics, Inc - Recent Pipeline Updates 38 Melinta Therapeutics, Inc - Dormant Projects 45 Melinta Therapeutics, Inc - Company Statement 46 Melinta Therapeutics, Inc - Locations And Subsidiaries 47 Head Office 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Melinta Therapeutics, Inc, Key Information 5 Melinta Therapeutics, Inc, Key Facts 5 Melinta Therapeutics, Inc - Pipeline by Indication, 2014 8 Melinta Therapeutics, Inc - Pipeline by Stage of Development, 2014 10 Melinta Therapeutics, Inc - Monotherapy Products in Pipeline, 2014 11 Melinta Therapeutics, Inc - Phase III, 2014 12 Melinta Therapeutics, Inc - Phase II, 2014 13 Melinta Therapeutics, Inc - Preclinical, 2014 14 Melinta Therapeutics, Inc - Discovery, 2014 15 Melinta Therapeutics, Inc - Pipeline by Target, 2014 34 Melinta Therapeutics, Inc - Pipeline by Route of Administration, 2014 35 Melinta Therapeutics, Inc - Pipeline by Molecule Type, 2014 36 Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2014 37 Melinta Therapeutics, Inc - Recent Pipeline Updates, 2014 38 Melinta Therapeutics, Inc - Dormant Developmental Projects,2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.